Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 201 - 250 out of 5,998

Document Document Title
WO/2013/107283A1
Disclosed are compound of formula (I) and pharmaceutically accepted salts and prodrugs thereof, wherein each of R1, R2, R3, R4, R5, R6, X1 and X2 is as defined in the description. These compounds are protein kinases inhibitors, especiall...  
WO/2013/059582A3
The disclosure relates to small molecules and methods, compositions, and kits comprising these small molecules. In still another embodiment, the disclosure relates to small molecules that inhibit HDAC activity. In yet another embodiment,...  
WO/2013/097773A1
The invention provides novel ethylene derivatives represented by Formula I, which may be used as selective estrogen receptor modulators (SERMs) and useful in the prophylaxis and/or treatment of estrogen-dependent conditions or conditions.  
WO/2013/063458A3
This document relates to inhibitors of G protein coupled receptor 6 kinase (GRK6) polypeptides as well as methods and materials for using such inhibitors to treat hematological malignancies, inflammation diseases, and autoimmune disorders.  
WO/2013/090454A2
The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of ...  
WO/2012/176856A3
The present invention provides a compound represented by the formula (I) or its salt, and a pesticide containing it as an active ingredient: (I) wherein each of R1 and R2 is a hydrogen atom, a halogen atom, alkyl, haloalkyl, alkoxy, halo...  
WO/2013/086229A1
The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. (The Formula I should be inserted here.) The compounds are ...  
WO/2013/078123A1
The invention relates to the heterocyclic compounds of Formula (I) as defined further herein, and pharmaceutical preparations thereof. The invention further relates to methods of treating cancer, immunological or neurological diseases us...  
WO/2013/063458A2
This document relates to inhibitors of G protein coupled receptor 6 kinase (GRK6) polypeptides as well as methods and materials for using such inhibitors to treat hematological malignancies, inflammation diseases, and autoimmune disorders.  
WO/2013/059582A2
The disclosure relates to small molecules and methods, compositions, and kits comprising these small molecules. In still another embodiment, the disclosure relates to small molecules that inhibit HDAC activity. In yet another embodiment,...  
WO/2013/014204A3
The present invention relates to compounds of the formula I, wherein Ht, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cat...  
WO/2013/043491A1
Corrosion of metallic tubulars in an oil, gas or geothermal well may be inhibited by introducing into the well a dithiazine derivative. The dithiazine may be isolated from a whole spent fluid (WSF) formed by reaction of hydrogen sulfide ...  
WO/2012/149189A3
This disclosure relates to a photovoltaic cell that includes a first electrode, a second electrode, and a photoactive layer disposed between the first and second electrodes. The photoactive layer includes a photoactive polymer containing...  
WO/2013/012665A3
Embodiment of the present disclosure can include a compound, a structure bonded to the compound, and the like. In an embodiment, the compound can be a linker between an agent and a structure, where the agent can be a dye or a pigment and...  
WO/2013/029294A1
Disclosed in the present invention is a 2-sulfhydryl-4,5-dimethyl-1,3,4-thiadiazole (A), a lithium salt (B), a diploid (C) and a synthesis process thereof. The micromolecule thiadiazole of the structure and derivates thereof can be used ...  
WO/2013/031694A1
A compound represented by general formula or a salt thereof is useful as an antifungal agent. (In the formula, R1 and R2 may be the same or different and each represents a halogen atom, a cyano group, a nitro group, an optionally substit...  
WO/2013/024168A1
The present invention relates to a compound of formula (IA), wherein G1 is lower alkyl; lower alkyl substituted by one or more halogens; cycloalkyl; tetrahydropyran-4-yl; phenethyl; phenethyl substituted by one or more halogens; phenoxym...  
WO/2013/022047A1
The present invention provides a compound which has an inhibitory activity on lysine-specific demethylase 1 and is useful as a medicinal agent such as a prophylactic or therapeutic agent for cancer and central nervous system diseases. Th...  
WO/2013/018735A1
The purpose of the present invention is to provide a novel compound which has an anti-fungal activity on pathogenic fungi including fungi belonging to the genus Candida, the genus Aspergillus and the genus Trichophyton and is useful as a...  
WO/2013/019731A2
A compound of formula: wherein R1, L A, R, and n are defined herein, is useful for treating various disorders, including diarrhea.  
WO/2010/063862A3
Chemical compounds derived from the 5,6-dihydrodibenzo[b,f][1,4,5]thia¬≠diazepine heterocyclic system and the use thereof as pharmaceutical compositions for the treatment of diseases of the central nervous system that are caused by a ser...  
WO/2013/014204A2
The present invention relates to compounds of the formula I, wherein Ht, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cat...  
WO/2013/012665A2
Embodiment of the present disclosure can include a compound, a structure bonded to the compound, and the like. In an embodiment, the compound can be a linker between an agent and a structure, where the agent can be a dye or a pigment and...  
WO/2013/004642A1
The present invention relates to a compound of formula (IA) The present invention also relates to the use of the compound of formula IA for treating certain neurodegenerative disorders characterized by cytotoxic TAU misfolding and/or agg...  
WO/2013/005157A1
Provided herein is novel compound of the general formula (I), its tautomeric forms, its stereoisomers, its analogs, its prodrugs, its isotopes, its N- oxides, its metabolites, its pharmaceutically acceptable salts, its polymorphs, its so...  
WO/2012/149335A3
The invention relates to compositions having RGS (regulator of G-protein Signaling) inhibiting activity, and methods of use thereof. In some embodiments, RGS-inhibiting compositions find use in research on or treatment of disease states ...  
WO/2012/176856A2
To provide a novel pesticide. The present invention provides a compound represented by the formula (I) or its salt, and a pesticide containing it as an active ingredient: (I) wherein each of R1 and R2 is a hydrogen atom, a halogen atom, ...  
WO/2012/175654A1
Tetraline sulfonamides derivatives highly specific towards CA IX and/or CA XII human carbonic anhydrase for targeting solid tumors.  
WO/2012/170536A1
The present invention describes [1,2,4]thiadiazine 1,1-dioxide compounds and pharmaceutically acceptable salts thereof, which are useful in lowering serum uric acid in a patient in need thereof comprising administering to the patient a t...  
WO/2012/162323A1
A method for treating hypertension in a subject in need thereof (e.g., wherein said treatment does not result in an increase in serum uric acid levels, abnormally elevated serum uric acid levels, hyperuricemia, serum uric acid levels of ...  
WO/2012/082893A3
High performance organic photovoltaic cells based on donor acceptor polymers in the active layer. A composition comprising: at least one copolymer comprising at least one first donor moiety and at least one first acceptor moiety in the c...  
WO/2012/147516A1
[Problem] To provide a GPR40 activating agent having as an active ingredient a novel compound having a GPR40 agonist action, or a salt thereof, a solvate of the compound or salt, or the like; in particular, an insulin secretagogue or an ...  
WO/2012/149335A2
The invention relates to compositions having RGS (regulator of G-protein Signaling) inhibiting activity, and methods of use thereof. In some embodiments, RGS-inhibiting compositions find use in research on or treatment of disease states ...  
WO/2012/147764A1
Provided is a novel compound having NPY Y5 receptor antagonistic activity. It was discovered that a compound represented by (1) (where R1 is an optionally substituted alkyl and the like; p, q, and r are each independently 0 or 1; ring A ...  
WO/2012/149189A2
This disclosure relates to a photovoltaic cell that includes a first electrode, a second electrode, and a photoactive layer disposed between the first and second electrodes. The photoactive layer includes a photoactive polymer containing...  
WO/2012/142671A1
The present invention provides compounds of Formula (I): and salts, racemates, isomers, diastereoisomers, enantiomers, hydrates, solvates, N-oxides, pharmaceutically acceptable derivatives or prodrugs thereof. Also provided the use of th...  
WO/2012/140251A1
The invention relates to a rubber composition for the production of tyres, containing one or more diene elastomers, one or more reinforcing fillers and a vulcanisation system. The composition is characterised in that the vulcanisation sy...  
WO/2012/138734A1
In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula : (I) and tautomers and stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said ...  
WO/2012/126570A1
The invention relates to combinations having at least one bicyclic or tricyclic ring system, which is connected by acetylene ethylene or difluoroethylene bridges, to the application thereof in high frequency components, to liquid crystal...  
WO/2012/121168A1
The purpose of the present invention is to provide: a novel compound having an excellent CK2-inhibiting activity and high safety; and use applications of the compound. Provided are: a CK2 inhibitor comprising, as an active ingredient, a ...  
WO/2011/107283A3
The invention relates to a composition comprising taurolidine and/or the hydrolysis products thereof and also a biodegradable (co)polymer or inorganic matrix for use as an implant for treating local infections of the skeleton and soft ti...  
WO/2012/082893A2
High performance organic photovoltaic cells based on donor acceptor polymers in the active layer. A composition comprising: at least one copolymer comprising at least one first donor moiety and at least one first acceptor moiety in the c...  
WO/2012/079164A1
The present invention is directed to activators of cylindrical proteases ("ACPs"), particularly ClpP, and the role thereof in the diagnosis and treatment of bacterial infections. A number of ACPs were identified that activate caseinolyti...  
WO/2012/050484A3
The invention relates to organic chemistry, more specifically to novel biologically active compounds in the form of 5-amino-1,2,4-thiadiazole derivatives of general formula (I), where X may be ONO2 or NHR3; R1, R2, R3 may be the same or ...  
WO/2012/077478A1
Aspects of the present invention can provide a novel phenanthrothiadiazole compound with the lowest excited triplet level T1 that is high, the phenanthrothiadiazole compound being capable of forming a stable amorphous film. Furthermore, ...  
WO/2012/070066A1
The present invention relates to a process for the preparation of substantially pure Taurolidine.  
WO/2012/029032A3
The present invention relates to heterocyclic compounds of Formula (1), in all their stereoisomeric and tautomeric forms; and their pharmaceutically acceptable salts, solvates, polymorphs, prodrugs, carboxylic acid isosteres and N-oxides...  
WO/2012/062210A1
The compound of formula (I), pharmaceutically acceptable salts thereof, solvates thereof, chelates thereof, non-covalent complex thereof or produgs of compounds mentioned above or the mixture of any form above mentioned are provided. The...  
WO/2011/162514A3
The present invention provides a novel method for preparing [1,2,3]-oxathiazolidine-2,2-dioxide or [1,2,5]-thiadiazolidine-1,1-dioxide derivatives. According to the manufacturing method of the present invention, it is possible to conveni...  
WO/2012/050484A2
The invention relates to organic chemistry, more specifically to novel biologically active compounds in the form of 5-amino-1,2,4-thiadiazole derivatives of general formula (I), where X may be ONO2 or NHR3; R1, R2, R3 may be the same or ...  

Matches 201 - 250 out of 5,998